Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Lisata Therapeutics, Inc.

< Previous 1 2 Next >
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Present at BIO CEO & Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Present at NobleCon19 Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Participation in Upcoming Conferences in October
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Participation in InfoSec World 2023
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Participation in Upcoming Conferences in September
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.